Organon (OGN) Surges 39% on $12 Billion Merger Speculation
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowOrganon & Co. (OGN) experienced a significant increase of 38.8% week-on-week following reports of a potential $12 billion acquisition by Sun Pharmaceutical Industries. No official confirmation has been issued regarding the merger. Additionally, Organon reported a decreased net income of 78% to $187 million in 2024, with revenues down 3% to $6.2 billion. In the fourth quarter, the company recorded a net loss of $205 million, compared to a net income of $109 million the previous year, while quarterly revenues also declined by 5.3% to $1.5 billion.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Organon & Co. (OGN)
Organon is a women’s-health-focused pharmaceutical company spun off from Merck.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
OGN stock page and all news →Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
